CompletedNCT01662310
Paliperidone Compared With Placebo to Study Schizophrenia Relapse
About this title
Read the official source — NCT01662310Medication studyAges 18+China
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Baoding and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 201
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China
- Age range
- Over 18 Years
- Official registry ID
- NCT01662310
- Official title
Show the full official title
Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBaoding · Beijing · Changsha
11 more locations
- Chengdu
- Guangzhou
- Harbin
- Kunming
- Nanjing
- Shanghai
- Taiyuan
- Tianjin
- Wuhan
- Xi'an
- Xinxiang
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone and Placebo.
Who was this study for?
Listed age limits: from 18 years.
